Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 3 7Phase 1/2 2Phase NA 1Phase 4 1Phase 2/3 1Phase 1 1

Status

Terminated 2Recruiting 2Not yet recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 1Advanced Non-small Cell Lung Cancer 1

Interventions

pembrolizumab 109Cyclophosphamide 85fludarabine 67Carboplatin 59Injections 58Bevacizumab 52Specimen Handling 42Gemcitabine 41Paclitaxel 40Magnetic Resonance Spectroscopy 40venetoclax 38Nivolumab 38Cisplatin 37Dexamethasone 35Biopsy 34Temozolomide 31Docetaxel 29atezolizumab 27Oxaliplatin 26Capecitabine 26Pemetrexed 25Fluorouracil 25toripalimab 24abemaciclib 24Irinotecan 24Azacitidine 24Fulvestrant 23Rituximab 21fludarabine phosphate 20durvalumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × Platinum Compounds × Clear all
NCT04486833 2026-01-21

Acclaim-1

Genprex, Inc.

Phase 1/2 Recruiting
158 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05416775 2022-08-19

Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1/2 Recruiting
168 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡